Clinical Studies with the Nal-Glu GnRH Antagonist

Because of the existence of anaphylactoid side effects following the subcutaneous (sc) injection of first generation antagonists of the [D-Arg6] class, there have been few clinical trials using GnRH antagonists in humans. These agents cause mast cell degranulation and histamine release [1, 2]. Recently, new classes of compounds have been designed and are available for phase 1 clinical trials.